COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

BACKGROUND: In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD). OBJECTIVE: Because it is believed that type...

Descripción completa

Detalles Bibliográficos
Autores principales: Ungar, Benjamin, Glickman, Jacob W., Golant, Alexandra K., Dubin, Celina, Marushchak, Olga, Gontzes, Alyssa, Mikhaylov, Daniela, Singer, Giselle K., Baum, Danielle, Wei, Nancy, Sanin, Antonio, Gruenstein, Diana, Lebwohl, Mark G., Pavel, Ana B., Guttman-Yassky, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558098/
https://www.ncbi.nlm.nih.gov/pubmed/34737108
http://dx.doi.org/10.1016/j.jaip.2021.10.050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558098/
https://www.ncbi.nlm.nih.gov/pubmed/34737108
http://dx.doi.org/10.1016/j.jaip.2021.10.050

Ejemplares similares